Bibliography
- EHRLICH P: Collected Studies on Immunity Vol. II. John Wiley, New York, USA (1906).
- HIMMELWEIT B: The Collected Papers of Paul Ehrlich. Pergamon Press, Oxford (1975).
- KUFE DW, NADLER L, SARGENT L et al.: Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. cancer Res. (1983) 43:851–857.
- HAKOMORI S, KANAGI R: Glycosphingolipids as tumor-associated and differentiation markers. J. Natl. Cancer Inst. (1983) 71:231–251.
- AZIZ KJ, MAMIM PE, HACKETT JL, TSAKERIS TM: Perspectives in laboratory management. Tumor markers: the premarket review and approval process. Am. Clin. Lab. (1993) 1:13–15.
- POTTER VR: On the road to the blocked ontogeny theory. Adv. Oncol (1988) 4:1–8.
- CHO-CHUNG YS: Site-selective 8-chloro-cyclic adenosine 3',5'-monophosphate as a biologic modulator of cancer: Restoration of normal control mechanisms. J. Nail. Cancer Inst. (1989) 81:982–987.
- RITTENHOUSE HG, MANDERINO GL, HASS GM: Mucin-type glycoproteins as tumor markers. Lab. Med. (1985) 16:556–560.
- FEIZI T: Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are oncodevelopmental antigens. Nature (1985) 314:53–57.
- REISFELD RA, CHERESH DA: Human tumor antigens. Adv. Immunol (1987) 40:323–377.
- LLOYD KO, OLD LJ: Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. Cancer Res. (1989) 49:3445–3451.
- BODEY B, SIEGEL SE, KAISER HE: Molecular Markers of Brain Tumor Cells: Implications for Diagnosis, Prognosis, and Antineoplastic Biologic Therapy Springer-Kluwer Academic Publishers, Dordrecht (2004).
- ••A volume providing extensive discussion ofresults in molecular marker and therapeutic target research in brain tumours.
- BODEY B: Genetically engineered antibodies for direct anti-neoplastic treatment and neoplactic cells directed delivery of various therapeutic agents. Expert Opin. Biol. Ther. (2001) 1:603–617.
- BODEY B: The significance of immunocytochemistry in the diagnosis and therapy of neoplasms. Expert Opin. Biol. Ther. (2002) 2:371–393.
- KOHLER G, MILSTEIN C: Continuous culture of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495–497.
- SONGSIVILAI S, LACHMANN PJ: Antibody engineering: current status and future development. Asian Pacific J. Allergy Immunol (1990) 8:53–60.
- VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254:1643–1647.
- HOUGHTON AN, SCHEINBERG DA: Monoclonal antibodies: potential applications to the treatment of cancer. Semin. Oncol. (1986) 13:165–179.
- COIFFIER B: Monoclonal antibodies in the treatment of neoplastic hematologic diseases. Bull. Cancer (2000) 87:839–845.
- •Important paper reviewing the possibilities for the employment of cancer cell-directed immunotherapy in the treatment of non-solid malignancies.
- PENAULT-LLORCA FM, BALATON AJ: Monoclonal antibodies in oncology: applications in diagnosis, prognosis and prediction of response to therapy on tissue specimens. Bull. Cancer (2000) 87:794–803.
- ••Thoroughly reviews the importance ofimmunohistochemistry in the initial and differential diagnosis of cancer.
- GABRILOVE JL: Differentiation factors. Semin. Oncol. (1986) 13:228–233.
- TALMADGE JE, HERBERMAN RB: The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat. Rep. (1986) 70:171–182.
- SKERRA A, PLUCKTHUN A: Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science (1988) 240:1038–1041.
- BETTER M, CHANG CP, ROBINSON RR, HORWITZ AH: Escherichia coli secretion of an active chimeric antibody fragment. Science (1988) 240:1041–1043.
- RIECHEMANN L, FOOTE J, WINTER G: Expression of an antibody Fv fragment in myeloma cells. J. MoL Biol.(1988) 203:825–828.